Introduction
The extracellular matrix (ECM) is a complex organization of secreted molecules. The major constitutive components of the ECM include collagens, elastin, fibronectin, hyaluronic acid and proteoglycans. Together these molecules form a network that provides structural support for tissues and delivers environmental signals that regulate cell behaviour. However, there exists a unique subset of ECM molecules that are not constitutively expressed. Found at high levels during development, but absent from most healthy adult tissues, these proteins are specifically induced at sites of tissue injury. These molecules have been termed 'matricellular proteins' and include the CCN family (CCN1-6), galectins (Gal), fibulins, osteopontin (OPN), periostin, secreted protein acidic and rich in cysteine (SPARC), small leucine rich proteoglycans (SLPRs), tenascin-C (TNC) and thrombospondins-1 and -2 (TSP-1/2). Despite their structural diversity, these molecules possess a number of defining common features in addition to their distinct pattern of expression. They are key orchestrators of cell behaviour; this is mediated by their multimodular structure, which confers the ability to interact with a large number of diverse binding partners such as cell surface receptors, other ECM molecules, hormones, growth factors and cytokines. Moreover, they exert control over a wide range of cell functions in a highly context-and cell type-specific manner. Finally, although highly expressed during development, mice with targeted disruptions in these genes exhibit grossly normal phenotypes until subjected to tissue injury, whereupon they exhibit abnormal tissue repair. There is a large body of evidence supporting a major role for these proteins in driving the response to tissue injury 1, 2 . The aim of this review is to discuss how the ECM drives persistent inflammation upon tissue damage to the joint in rheumatoid arthritis (RA).
Discussion
The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) , and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.
Control of tissue repair by the ECM
Tissue repair is a dynamic and highly organized process that can be divided into three distinct but overlapping phases: inflammation, new tissue formation and tissue remodelling. During wound healing, a temporary matrix is deposited that acts as a template for repair and is eventually replaced by new structural ECM components, including collagen and fibronectin, to restore the physical integrity of the tissue and re-establish cellular homeostasis. Matricellular proteins are specifically up-regulated at distinct points during wound healing. Their expression is transient; mRNA synthesis is down-regulated and protein cleared from the site before the end of tissue repair. Their contribution to effective tissue repair has been reviewed in an issue dedicated to matricellular proteins 3 , and Figure 1 summarizes the expression and function of some of the key matricelluar proteins during tissue injury. Whilst their importance in driving adhesion, migration, matrix deposition, angiogenesis, proliferation and survival in stromal cells such as fibroblasts, endothelial cells and keratinocytes during tissue formation and remodelling has long been established, in the last decade it has emerged that matricellular proteins also play a role in the initial inflammatory response to tissue injury .
The ECM supports immune cells and drives inflammation during tissue repair
The inflammatory response following tissue damage is characterized by infiltration of a range of immune cells, including neutrophils, macrophages and lymphocytes, to the site of injury. The expression of cytokines, chemokines, proteases and growth factors by these cells orchestrates subsequent phases of tissue repair including tissue debris clearance and pathogen resorption, recruitment and activation of further cells and cell types, and new tissue formation and remodelling. It is becoming increasingly apparent that matricellular proteins have a direct impact The role of the ECM in tissue repair. The first response to injury includes the formation of a blood clot consisting of platelets and a fibrin/fibronectin-rich provisional matrix to prevent blood loss. Soluble cytokine and growth factors released by aggregated platelets promote the infiltration of a range of cell types into the provisional matrix. Neutrophils and macrophages cleanse the wound by removing debris, and re-epithelialization is promoted through the migration and proliferation of keratinocytes. The provisional matrix is replaced by granulation tissue which comprises new blood vessels, macrophages and activated fibroblasts that secrete type III collagen and fibronectin. Some fibroblasts differentiate into myofibroblasts that contract and bring the edges of the wound together. The final phase of wound healing starts about two weeks after tissue injury and lasts for at least one year. Most macrophages, fibroblasts and endothelial cells undergo apoptosis. Type III collagen is replaced by type I collagen that is reorganized and cross-linked to produce scar tissue with a higher tensile strength. Matricellular proteins are induced at distinct points after tissue injury and mediate effective tissue deposition and remodelling during repair
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. Red arrows represent inhibition, and green arrows indicate stimulation, of the delineated event. References are shown in brackets.
on inflammation in the early stages of tissue repair. This is discussed below and summarized in Table 1 .
A number of matricellular molecules have been shown to support the adhesion of different types of immune cells, others to promote immune cell migration, whilst some enhance immune cell survival and proliferation. Together, these data suggest that matricellular proteins provide an environment that allows immune cells to infiltrate and thrive at the site of tissue injury. These data also reveal that matricellular molecules have both distinct and overlapping functions during inflammation. For example, mice deficient in TNC or TSP-1 both exhibit lower numbers of macrophages in corneal or dermal wounds, respectively, indicating that these proteins promote macrophage infiltration or survival during wound healing 32, 38 . In contrast, macrophage infiltration into skin incisions is not impaired in OPN-deficient mice compared to wild-type mice; however, the level of tissue debridement is significantly reduced, indicating that OPN plays a role in macrophage activation during cutaneous wound healing 25 . Indeed, many matricellular proteins have also been shown to directly interact with immune cells to drive a pro-inflammatory phenotype. The mechanisms by which these functions are mediated are proving complex. For example, both OPN and TNC induce the expression of proinflammatory mediators in immune cells. OPN has been shown to mediate these effects via activation of a number of cell surface receptors; it induces the synthesis of specific cytokines, chemokines and proteases in primary murine arthritic synovial fibroblasts, macrophages and dendritic cells via activation of α9integrins 43, 44 , it induces cytokine synthesis in murine macrophage cell lines via activation of β3 integrins 45 and it stimulates CD4 T-cell migration and cytokine synthesis via activation of CD44 45, 46 . TNC can also induce cytokine, chemokine and protease expression using distinct mechanisms: activation of toll-like receptor 4 (TLR4) in primary human macrophages and synovial fibroblasts, and murine neutrophils 47, 48 and activation of α9 integrins in primary murine arthritic synovial fibroblasts, macrophages and dendritic cells 43, 44 . It achieves this via ligation of integrins using its third fibronectin type III like domain (FNIII) 43, 44 and activation of TLR4 via its fibrinogen-like globe (FBG) 47 . In addition to driving de novo synthesis of pro-inflammatory mediators, matricellular proteins can also bind directly to these mediators and modulate their activity. For example, TNC interacts with a range of growth factors including FGF, PDGF and TGFβ via its FNIII 4-5 repeats 49 and TSP-1 activates latent TGFβ 50, 51 . As such, these proteins may further potentiate inflammation by acting as a reservoir for soluble mediators enabling their presentation in an active form at high local concentrations to immune cells.
The pro-inflammatory activity of matricellular proteins is in part regulated by their tightly controlled expression during tissue repair, but can also be controlled by fellow members of the family. For example, whilst a pro-inflammatory role has been reported for the majority of these molecules, TSP-2 appears more prone to inhibiting inflammatory processes; it prevents T-cell migration and leukocyte rolling as well as suppressing pro-inflammatory cytokine synthesis and promoting the activation of regulatory T cells [52] [53] [54] . Thus, the complex interplay between these molecules during tissue repair appears to control both the induction and resolution of inflammation.
Together, these data reveal matricellular proteins as rather unique pro-inflammatory stimuli. Unlike most inflammatory mediators, such as cytokines, which comprise small, soluble molecules of a limited half-life, these molecules are large proteins that accumulate as part of a dense matrix specifically assembled at the site of injury. This physical presence enables them to provide a scaffold for immune cell adhesion and migration as well as forming a reservoir for soluble mediators of inflammation, but these molecules also directly interact with cells to stimulate inflammatory behaviour. This creation of a 'pro-inflammatory niche' by matrix molecules induced upon injury may shed new light on how we perceive the role of the ECM during tissue repair.
A pro-inflammatory niche in the RA joint In addition to their transient expression at sites of tissue repair, matricellular proteins are expressed at high levels in diseases characterized by chronic inflammation and extensive tissue destruction. This includes autoimmune diseases such as RA. The hallmark of RA is prolonged immune cell migration into the joint and synovial hyperplasia. Persistent synthesis of pro-inflammatory mediators by these infiltrating immune cells and resident fibroblasts causes chronic synovial inflammation and the production of an invasive pannus mediates destruction of healthy articular cartilage and bone. Matricellular proteins are predominantly absent from normal joints, however, SPARC was reported at high levels in RA synovial tissue and fluid as early as 1996 134 , and TNC expression has long been observed in the RA synovium, localized to areas of inflammation and fibrosis, specifically below the synovial lining, in the invading pannus, in fibrin-rich deposits and around blood vessels [135] [136] [137] [138] . More recently, an up-regulation in the expression of other matricellular proteins has been reported in the RA joint (Table 2 ). For example, OPN is found in the synovium and the invading pannus 139 , demonstrating a similar pattern of expression to Gal-3 Promotes pro-inflammatory cytokine production in macrophages and synovial fibroblasts via activation of TLR4 47
Promotes pro-inflammatory cytokine production in DCs and IL-17 production in DC-CD4 T-cell co-cultures 114
Promotes pro-inflammatory cytokine production in macrophages via regulation of microRNA-155 expression 115
Promotes pro-inflammatory mediator production in human and bovine chondrocytes via activation of TLR4 116
Promotes TLR4-dependent differentiation of macrophages into foam cells 117
Promotes MMP9 expression in neutrophils via activation of TLR4 48
Promotes pro-inflammatory cytokine production in macrophages and synovial fibroblasts via activation of α9 integrins 43 
Protein Function References
However, both exhibit a distinct pattern to Gal-1, which is detected in the RA synovium but excluded from the invading pannus
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. In considering the source of these matrix molecules during RA pathogenesis, the majority of studies examined their expression in synovial fibroblasts and found out that these cells synthesize large amounts of such matrix. In addition, however, immune cells can also supply matricellular molecules to the RA joint; myeloid cells of the RA synovium significantly contribute to TNC synthesis 141 and TSP-1 is expressed in RA monocytes 142 . It will be interesting to examine if other matricellular proteins are formed by immune cells and to compare the form and function of these molecules from different sources.
Evidence that matricellular proteins affect disease progression is also emerging (Table 2 ). For example, CCN1 enhances RA synovial fibroblast proliferation 143 suggesting that it may contribute to synovial hyperplasia. CCN1 and other molecules, such as TNC and OPN, drive the synthesis of pro-inflammatory mediators in isolated synovial fibroblasts and immune cells 43, 44, 47, 114, [144] [145] [146] implying that they possess a role in innate immune responses in RA. Furthermore, these three molecules may also impact adaptive immune events in the joint; each can drive T-cell polarization down the Th17 lineage in vitro 44, 114, 145, 147 . These are key pathological cell types that promote tissue erosion in RA and in vivo studies confirm the contribution of CCN-1, TNC and OPN in promoting Th17 cell generation in murine models of arthritic disease 44, 114, 145 . In vivo models also reveal further information about the role of matricellular proteins in disease pathogenesis. OPN null
TSP-1
Promotes activated CD4 T-cell adhesion via α4 β1 and α5β1 integrins 118
Promotes neutrophil and monocyte chemotaxis 119, 120
Promotes activation and expansion of CD4 T-cells via CD36/CD47 121
Promotes apoptosis in T-cells, monocytes and DCs 122
Promotes Treg cell differentiation via CD47 123
Regulates cytokine production in monocytes via CD36 124
Inhibits cytokine production in monocytes and DCs via CD47 125-127
Activates latent TGFβ1 50, 51
Drives Th17 responses 51
Promotes macrophage phagocytosis of apoptotic cells via CD36 128, 129
Promotes allosensitization capacity of antigen-presenting cells 130
Promotes DC phagocytic and tolerizing states 131
Inhibits TCR-mediated T-cell activation 132
TSP-2
Inhibits leukocyte rolling during wound healing 133
Inhibits TGFβ activation and T-cell and antigen-presenting cell migration during experimental glomerulonephritis 52
Inhibits production of pro-inflammatory cytokines and T-cell infiltration during RA 53
Promotes the activation of Tregs 54 Treatment with Gal-1 attenuates CIA severity through promotion of CD4 T-cell apoptosis 149
Treatment with Gal-1-nanogold complex attenuates CIA severity through promotion of CD4 T-cell apoptosis 164
Overexpression attenuates CIA severity through promotion of CD4 T-cell death 149, 150
Gal-1 chimeric molecule promotes apoptosis in granulocytes from RA synovial fluid 165
Gal-3 Expression is elevated in RA joint (synovial membrane, synovial fluid, sites of joint destruction) 140
Expression is induced in RA synovial fibroblasts after adhesion to cartilage oligomeric matrix protein 166
Promotes cytokine and chemokine production in RA synovial fibroblasts 151 Null mice are protected from joint inflammation and bone and cartilage destruction during AIA 47
Null mice exhibit reduced zymosan-induced joint inflammation 47
Expression correlates with pro-inflammatory cytokine expression in RA joint 141
Promotes expression of pro-inflammatory cytokines (including IL-17) in arthritic joints during AIA 114
Promotes pro-inflammatory cytokine production in synovial fibroblasts and macrophages via activation of α9 integrins 43
Induces α9-dependent IL-6 production in DCs and macrophages from mice with CIA and Th17 polarization 44
TSP-1 Expression is elevated in RA monocytes 142
Expressed in in RA synovial tissue 53 
Protein Expression/Function in RA References
, supporting in vitro data that establish this protein as a pro-inflammatory molecule. Intraarticular injection of TNC drives synovial inflammation and joint erosion in a TLR4 dependent manner. Moreover, whilst joint inflammation can be initiated in TNC null mice, these mice are protected from prolonged erosive joint destruction, implying that TNC is required for disease chronicity 47 . The different distribution of galectin family members in the joints of RA patients implies that they may play distinct roles in the RA synovium. Indeed, Gal-1 has been shown to promote the apoptisis of T-cells in vitro and intraperitoneal administration of exogenous Gal-1 or intraarticular overexpression mediated by lentiviral gene transfer during collagen induced arthritis (CIA) in mice attenuates disease severity by enhancing T-cell death 149, 150 . In contrast, Gal-3 promotes cytokine production in RA synovial fibroblasts 151 . Genetic deletion of Gal-3 or lentiviral-mediated knockdown of its expression in the joint attenuates CIA severity 150, 152 . Finally, administration of neutralizing monoclonal antibodies that recognize individual matricellular proteins has demonstrated positive therapeutic effects in murine models of RA. A number of studies show that treatment with anti-OPN antibodies attenuates CIA disease severity 153, 154 . Anti-CCN1 antibodies attenuate disease progression in CIA by reducing Th17 cell frequencies 145 . Anti-CCN2 monoclonal antibodies reduce CIA disease severity by reducing osteoclastogeneis in inflamed joints 155 , consistent with in vitro data showing that CCN2 enhances osteoclast activation
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. Exogenous administration of members of the thrombospondin family during murine models of joint disease also affects distinct processes during joint inflammation. Intraperitoneally administered TSP-1 peptides decreased the severity of peptidoglycan-polysaccharide-induced erosive arthritis in rats 157, 158 and intraarticular adenovirus-mediated expression of TSP-1 reduced CIA severity Together, these data indicate that a complex mixture of matrix molecules is deposited upon injury to the RA joint, which creates a niche that supports immune cells and synovial fibroblasts, and which is permissive for pro-inflammatory processes to occur. This idea of a specific microenvironment in the RA joint, first proposed by Kanayama et Promotes bone marrow stromal cell attachment 203
Promotes osteogenesis in vivo 204
Niches have also been proposed to play an important role in cancer development, both in the primary tumour, as well as at metastatic sites. Some studies indicate that tumours contain low numbers of cancer stem cells (CSCs), characterized by their capacity to selfrenew and initiate new tumours 173 . Similar to HSCs, these cells inhabit a specialized microenvironment, the CSC niche, which controls their maintenance and differentiation 174 . Tumour metastasis is a multistep process, involving the dissemination of cancer cells from the primary tumour site to distant tissues. The 'seed and soil' hypothesis by Paget 175 proposes that metastatic cells ('seeds') require a permissive microenvironment ('soil') for the generation of metastases at secondary sites. In the metastatic niche model, the formation of a pre-metastatic niche is required for tumour cell engraftment, and the subsequent formation of a metastatic niche promotes the growth of metastases 176 . Both the CSC and the metastatic niches contain a range of stromal as well as immune cells, ECM components, cytokines and growth factors 177 . Increasing evidence indicates that matricellular proteins are crucial components of haematopoietic niches, where they regulate key aspects of stem cell behaviour ( Table 3) Competing interests: declared in the article. Conflict of interests: none declared. Promotes pre-BII cell proliferation and differentiation 209
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Regulates growth and death of premature haematopoietic cells 210
Regulates proliferation and differentiation of bone marrow stromal cells 211
Metastatic niche Expressed in a range of tumours 212
Knockdown inhibits glioma cell growth 213
Promotes tumour growth and metastasis in vivo via increasing T cell apoptosis 214
Knockdown inhibits tumour growth and metastasis in vivo 215
Promotes lung cancer cell invasion in vitro and metastasis in vivo 216
Gal-3
Haematopoietic niche Expressed in myeloid cells, stromal cells and B cells in the bone marrow 217, 218
Suppresses GM-CSF-induced proliferation and gene transcription in bone marrow cells 217
Knockout mice exhibit modified bone marrow histology 219
Promotes differentiation of myeloid progenitor cells 219
Inhibits B cell differentiation into plasma cells in the bone marrow 218
Metastatic niche
Expressed in a range of tumours 220
Inhibition inhibits breast cancer cell growth in vitro and in vivo 221
Inhibits B cell lymphoma cell apoptosis 222
Overexpression promotes malignant transformation of thyroid follicular cells 223
Promotes breast carcinoma cell invasion in vitro 224 Negatively regulates stem cell numbers in the bone marrow 178
Fragments promote stem and progenitor cell migration, retention and release from the bone marrow 225
Inhibits HSC proliferation in vitro and in vivo 179
Metastatic niche Expressed in a range of tumours 226
Promotes ovarian cancer cell proliferation, migration, invasion and tumour formation 186
Promotes tumour growth and prostate cancer cell proliferation, migration and invasion 187
Fragment promotes hepatocellular carcinoma cell invasion via CD44 227
Knockdown in renal carcinoma cells increases apoptosis and decreases invasiveness 228
Overexpression promotes fibrosarcoma or pancreatic tumour growth and lung metastasis through inhibition of apoptosis 229
SPARC

Haematopoietic niche
Knockout mice have no defects in steady state haematopoiesis or haematopoieitic recovery after myeloablation 230
Promotes osteoblast formation, maturation and survival 231
Promotes erythroid colony forming capacity 230, 232
Promotes erythroid cell progenitor differentiation in zebrafish 233
Metastatic niche Expressed in a range of tumours 234
Overexpression reduces breast cancer cell invasion and colony formation in vitro and bone metastasis in vivo 235
Overexpression promotes glioblastoma invasion in vitro 236
Knockdown abrogates human melanoma cell tumourigenicity in vitro and in vivo 237
Inhibits tumour cell growth in vitro and in vivo 238
Overexpression inhibits tumour growth in vivo 239 Knockout mice exhibit impaired haematopoietic recovery after bone marrow ablation 180
Metastatic niche Expressed in a range of tumours 243
Knockdown reduces breast cancer cell migration, proliferation, tumour growth and lung metastasis 244
Knockdown reduces survival and outgrowth of lung metastases 188
Promotes the survival of Metastasis-initiating breast cancer cells by EnhancingWnt and Notch signalling 188
Promotes metastatic colonization 245
Inhibits IFNγ production by tumour-infiltrating lymphocytes 111
Overexpression promotes breast cancer cell invasion and proliferation through upregulation of MMP expression 246
Inhibits transmigration of T-lymphocytes in glioblastoma 247
TSP-1
Haematopoietic niche
Expressed by haematopoietic and stromal cells in the bone marrow 248
Inhibits osteogenic differentiation of MSCs through activation of TGFβ 249
Promotes adhesion of haematopoietic progenitor cells 248, 250
Inhibits megakaryocytopoiesis 251
Metastatic niche
Expressed in a range of tumours 252
Overexpression inhibits melanoma angiogenesis and lung metastasis in vivo 253
Promotes breast cancer cell migration in vitro and metastasis in vivo 254
Knockdown inhibits prostate tumour growth in vivo 255
Promotes the recruitment of M1 tumour-associated macrophages (TAMs) 256
Inhibits mammary tumour angiogenesis and growth in vivo 257 178, 179 . In contrast, TNC-deficient mice have no defects in steady state haematopoiesis; however, haematopoietic recovery after bone marrow ablation is impaired in these mice 180 . TNC was shown to promote the adhesion of HSCs to stromal cells and to promote the proliferation of hematopoietic stem and progenitor cells 181, 182 . Gal-1-expressing stromal cells were identified as a component for a pre-BII cell-specific niche in the bone marrow 183 . Matricellular protein expression in metastatic niches has also been shown to regulate different aspects of tumour progression and metastasis 184, 185 (Table 3) . For example, OPN promotes the proliferation, migration and invasion of various cancer cell types in vitro 186, 187 and TNC expression by breast cancer cells promotes their ability to metastasise into the lungs by enhancing cancer stem cell fitness 188 . Throughout this literature, there is a strong emphasis on matricellular proteins promoting stem and cancer cell survival, differentiation and proliferation. It will be interesting to see whether these molecules, which from their matrix in the RA joint can promote inflammation, also affect inflammation within the tumour stroma. Whilst inflammation is now widely recognized as a key feature of cancer disease progression, inflammation within the homeostatic environment of the bone marrow, however, would be extremely detrimental. Thus, the question arises as to what dictates the particular effects that the same matricellular protein can exert on different cells within different niches. The answer most likely lies in the precise combination of proteins that make up the niche together with the cell surface receptor repertoire of the interacting cells to enable a context-specific response.
A number of studies have gone into addressing these issues. Primary tumours do not metastasize to all tissues, and indeed tumours of distinct types often migrate to different secondary sites. This suggests that a specific type of soil is required by specific tumours seeds 176 . Moreover, metastasis of the same tumour type to different secondary sites is driven by very different molecular mechanisms. Genes that are specifically associated with breast cancer cells that metastasize to the lungs are largely distinct from the
TSP-2
Haematopoietic niche
Expressed by MSCs in the bone marrow 208, 258
Expressed by haematopoietic stem and progenitor cells 259
TSP-2 deficiency increases osteoprogenitor cell numbers and proliferation 260, 261
Inhibits MSC proliferation 258
Promotes platelet release from megakaryocytes 262
Promotes adhesion of haematopoietic stem and progenitor cells 259
Metastatic niche
Expressed in a range of tumours 263
Overexpression inhibits melanoma invasiveness in vitro and liver metastasis in vivo 264
Deficiency promotes skin carcinoma tumour angiogenesis and decreases tumour cell apoptosis 265
Overexpression inhibits squamous cell carcinoma tumour growth and angiogenesis in vivo 266
Overexpression inhibits pancreatic cancer cell invasion in vitro 267
Knockdown inhibits invasion of tumour-derived pancreatic stellate cells 268 gene-expression signature of breast cancer cells that exhibit high potential to metastasize to the brain or to bone [269] [270] [271] . Amongst these gene sets, for example TNC was enriched in those breast cancer cells that spread to the lungs, but not to other sites. This implies that there is not one type of unifying ECM environment that comprises a metastatic niche but there exists specific ECM signatures for specific cancers. Recently, two distinct types of haematopoietic niche have also been defined: the osteoblastic niche, localized at endosteal bone surfaces and proposed to promote HSC quiescence, and the vascular niche, localized at the surfaces of sinusoidal blood vessels and proposed to promote HSC proliferation and differentiation
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. It will be of great interest to examine the composition of the ECM in each of these locations.
Conclusion
Here we describe a model for RA disease pathogenesis in which the synovial environment is key to determining the behaviour of infiltrating immune cells and resident fibroblasts ( Figure  2 ). Analogous to the metastatic niche 'seed and soil' paradigm, where the extracellular environment is essential for supporting tumour cell survival, we propose that the creation of an extracellular niche within the synovium helps to sustain chronic inflammation. Synovial fibroblasts from RA joints autonomously induce joint disease upon systemic injection into mice, but do not cause inflammation in any other tissue, indicating that factors endogenous to the synovium support site-specific disease induction.
Figure 2:
Model of how the pro-inflammatory niche drives sustained inflammation in RA. Many ECM molecules that are induced in response to tissue damage are found at high levels in the RA joint. Here we propose that they form a pro-inflammatory niche which supports immune cell infiltration, and is permissive for both infiltrating immune cells and tissue resident cells to proliferate and thrive. By virtue of their multimodular domain structures, ECM molecules also interact with a variety of cell surface receptors in a number of types to actively regulate many different aspects of inflammatory cell behaviour. Finally, this ECM also integrates signals from soluble mediators by acting as a reservoir for cytokines, chemokines and growth factors. Lack of effective control of the expression of these matrix molecules, coupled with or caused by, progressive tissue damage serves to create an environment that contributes to a prolonged immune response in the RA joint. Development of agents that block the pro-inflammatory action of this niche, either alone or coupled to established anti-inflammatory agents, may reveal new strategies to locally dampen chronic inflammation in the RA joint without globally ablating the immune response.
Targeting the metastatic niche, as well as the metastasizing cell, is proving essential for effective prevention of tumor progression 184, 188, 274, 275 . Identification of a pro-inflammatory niche in the joint could also provide an entirely novel means of treating RA. The expression of injury specific ECM molecules not found in healthy tissues may serve as a postcode to direct delivery of anti-inflammatory agents to the inflamed synovium. Combination of this approach with agents that prevent ECM-mediated inflammation may provide a powerful, tissue-specific strategy for RA treatment.
Indeed, in the cancer field using TNC as a means to deliver cytotoxic agents to glioma sites has proved an effective means of reducing tumour burden . Expanding on this theme, Schwager et al, in a recent and very elegant study, conjugated monoclonal antibodies raised against fibronectin EDA, a splice variant of this matrix glycoprotein that is specifically induced during tissue injury and found at high levels in RA synovia, to the anti-inflammatory cytokine IL-10. These conjugates were systemically administered during murine CIA and demonstrated significant inhibition of the progression of established arthritis
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. This approach shows that using injury-specific ECM to deliver anti-inflammatory agents to the RA joint may be therapeutically useful in treating RA; fibronectin-EDA-antibody-IL10 conjugates are now being tested in the clinic. However, the data indicating that these matrix molecules also actively contribute to driving inflammation in RA may offer additional therapeutic benefit. However, before this can be achieved there remain many intriguing questions to answer. Why do many matricellular molecules exert the same pro-inflammatory effects? Why does a single matricellular molecule exhibit two or more mechanisms for inducing inflammatory cytokine synthesis? Which molecules (and which mechanisms) are key players in driving inflammation in RA and which merely constitute collateral damage? This question of redundancy, i.e. should we target one or all matricellular molecules, aim to block single or common pro-inflammatory pathways, must be addressed to fully understand how this complex matrix functions in RA and if we wish to use matricellular protein expression in the joint for anything other than a sophisticated delivery system.
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